Revisiting antiangiogenic therapy to target prostate cancer metabolism

This three-year Project Grant award of $739,289 from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) will fund research to revisit antiangiogenic therapy approaches to target prostate cancer metabolism. The University of Texas M.D. Anderson Cancer Center in Houston, Texas will lead the effort starting September 1, 2022. As part of the award, two co-investigators at Baylor College of Medicine will utilize mass spectrometry imaging to analyze the metabolic signatures of prostate cancer cells and tissue samples. This will help the research team interpret acquired data and prepare publications describing achieved results. The funding will support innovative medical research with the goals of transforming military and public health care through investigating battlefield medical solutions and other impactful studies.